PENGARUH MOTIVASI DAN KEDISIPLINAN TERHADAP KINERJA PEGAWAI DINAS PEMUDA, OLAH RAGA, KEBUDAYAAN DAN PARIWISATA KABUPATEN LAMPUNG UTARA

Dalam kewenangan otonomi yang luas ini tercakup keleluasaan daerah untuk menyelenggarakan pemerintahan yang meliputi kewenangan bidang pemerintahan kecuali kewenangan di bidang polilik luar negeri, pertahanan keamanan, peradilan, moneter data fiskal, serta kewenangan bidang lainnya yang akan ditetapkan dengan Peraturan Pemerintah. Ada pengaruh motivasi dan kedisiplinan secara bersama-sama terhadap kinerja pegawai Dinas Pemuda Olahraga Kebudayaan dan Pariwisata Kabupaten Lampung Utara. Penelitian ini menggunakan pendekatan survey yaitu penelitian lapangan dimana pengumpulan data dilakukan dengan cara mengedarkan kuesioner terhadap responden yang telah ditetapkan. Berdasarkan hasil analisis yang dilakukan menunjukkan bahwa secara parsial dan simultan terdapat pengaruh motivasi dan kedisiplinan terhadap kinerha pegawai Dinas Pemuda Olah Raga Kebudayaan dan Pariwisata Kabupaten Lampung Utara menunjukkan. Hasil distribusi jawaban responden dan jumlah keseluruhan dan persentase memperlihatkan menunjukkan bahwa secara umum memberikan gambaran bahwa motivasi pegawai di Dinas Pemuda Olah Raga Kebudayaan dan Pariwisata Kabupaten Lampung Utara adalah baik, gambaran kedisiplinan pegawai di Dinas Pemuda Olah Raga Kebudayaan dan Pariwisata Kabupaten Lampung Utara juga tergolong baik dan gambaran kinerja pegawai di Dinas Pemuda Olah Raga Kebudayaan dan Pariwisata Kabupaten Lampung Utara tergolong baik

Exploring genetic resistance to infectious salmon anaemia virus in Atlantic salmon by genome-wide association and RNA sequencing

Funding The authors gratefully acknowledge funding from BBSRC (BB/R008612/1, BB/R008973/1), in addition to BBSRC Institute Strategic Programme Grants to the Roslin Institute (BB/P013759/1 and BB/P013740/1).Peer reviewedPublisher PD

Transcultural Diabetes Nutrition Therapy Algorithm: The Asian Indian Application

India and other countries in Asia are experiencing rapidly escalating epidemics of type 2 diabetes (T2D) and cardiovascular disease. The dramatic rise in the prevalence of these illnesses has been attributed to rapid changes in demographic, socioeconomic, and nutritional factors. The rapid transition in dietary patterns in India—coupled with a sedentary lifestyle and specific socioeconomic pressures—has led to an increase in obesity and other diet-related noncommunicable diseases. Studies have shown that nutritional interventions significantly enhance metabolic control and weight loss. Current clinical practice guidelines (CPGs) are not portable to diverse cultures, constraining the applicability of this type of practical educational instrument. Therefore, a transcultural Diabetes Nutrition Algorithm (tDNA) was developed and then customized per regional variations in India. The resultant India-specific tDNA reflects differences in epidemiologic, physiologic, and nutritional aspects of disease, anthropometric cutoff points, and lifestyle interventions unique to this region of the world. Specific features of this transculturalization process for India include characteristics of a transitional economy with a persistently high poverty rate in a majority of people; higher percentage of body fat and lower muscle mass for a given body mass index; higher rate of sedentary lifestyle; elements of the thrifty phenotype; impact of festivals and holidays on adherence with clinic appointments; and the role of a systems or holistic approach to the problem that must involve politics, policy, and government. This Asian Indian tDNA promises to help guide physicians in the management of prediabetes and T2D in India in a more structured, systematic, and effective way compared with previous methods and currently available CPGs

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.